Scheme

Nippon India Pharma Fund

Holds 36 companies worth ₹8,919 Cr in Sept 2026.

Fund house
NipponThe fund house that runs this scheme.
AUM
₹9,166 CrNippon India Pharma Fund's AUM at the end of 30 Sept 2026, as AMFI reports it. Down 3.3% on Aug 2026, ₹9,479 Cr.
Largest holding
Sun Pharmaceutical Ind LtdSun Pharmaceutical Ind Ltd is 11.7% of this scheme's NAV.
Fund manager
Sailesh Raj BhanRuns it since 1 Jun 2004, as the fund house dates it.

Holdings^{(Oct 2012 – Sept 2026)}

Holdings in Sept 2026. Tick up to 2 to plot them.
Plot	36 companies ·	₹ Cr
	Sun Pharmaceutical Ind Ltd	1,073
	Divi s Laboratories Limited	651
	Lupin	565
	Cipla	551
	Dr Reddy s Laboratories Limited	499
	Apollo Hospitals Enterprise Limited	448
	Mankind Pharma Limited	402
	Sai Life Sciences Limited	359
	Ajanta Pharmaceuticals Limited	331
	GLAXO SMITHKLINE PHARMA	285
	IPCA Laboratories Limited	263
	Max Healthcare Institute Limited	247
	Vijaya Diagnostic Centre Limited	240
	Medplus Health Services Limited	232
	Gland Pharma Limited	232
	Abbott India Limited	213
	Piramal Pharma Limited	205
	Thyrocare Technologies Ltd	205
	Dr Lal Path Labs Limited	199
	Alkem Laboratories Limited	167
	Aurobindo Pharma	151
	Narayana Hrudayalaya Limited	148
	Suraksha Diagnostic Limited	138
	Syngene International Limited	128
	Emcure Pharmaceuticals Limited	125
	Pfizer	123
	Akums Drugs and Pharmaceuticals Limited	111
	Anthem Biosciences Limited	109
	Fortis Healthcare Limited	104
	Biocon	92.7
	Aventis Pharma	91.8
	SANOFI CONSUMER HEALTHCARE	81.3
	Molbio Diagnostics Limited	49.8
	Indoco Remedies	44
	Astra IDL Ltd	38.7
	Concord Biotech Limited	15.4

Sun Pharmaceutical Ind Ltd
Divi s Laboratories Limited

Market value of each ticked company in Nippon India Pharma Fund, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.
Month	Sun Pharmaceutical Ind Ltd	Divi s Laboratories Limited
Sept 2025	₹997 Cr	₹569 Cr
Oct 2025	₹1,058 Cr	₹674 Cr
Nov 2025	₹1,146 Cr	₹583 Cr
Dec 2025	₹1,076 Cr	₹544 Cr
Jan 2026	₹998 Cr	₹515 Cr
Feb 2026	₹1,087 Cr	₹545 Cr
Mar 2026	₹1,099 Cr	₹506 Cr
Apr 2026	₹1,158 Cr	₹553 Cr
May 2026	₹1,153 Cr	₹501 Cr
Jun 2026	₹1,156 Cr	₹494 Cr
Jul 2026	₹1,235 Cr	₹605 Cr
Aug 2026	₹1,172 Cr	₹663 Cr
Sept 2026	₹1,073 Cr	₹651 Cr

Fig. 1.Market value of each ticked company in Nippon India Pharma Fund, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Allocation^{(Sept 2026)}

Market cap

		% of NAV
Large Cap	4	29.71

Mid Cap	14	39.02

Small Cap	17	28.04

Unlisted	1	0.54

Cash & others		2.69

Sectors

Companies

Fig. 2.This scheme's holdings, by market cap, by sector and by company. Hover a slice or a row; click a slice to open it.

Buying and selling, month by month^{(Oct 2025 – Sept 2026)}

Buying and selling, month by month. Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Fig. 3.Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Portfolio^{(Sept 2026)}

Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures. Click a column's header to sort by it.

Sun Pharmaceutical Ind Ltd	Equity	Pharmaceuticals & Biotechnology	59.1L	1,073	11.71
Divi s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	7.01L	651	7.10
Lupin	Equity	Pharmaceuticals & Biotechnology	27.8L	565	6.17
Cipla	Equity	Pharmaceuticals & Biotechnology	41L	551	6.01
Dr Reddy s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	40.5L	499	5.45
Apollo Hospitals Enterprise Limited	Equity	Healthcare Services	5.49L	448	4.89
Mankind Pharma Limited	Equity	Pharmaceuticals & Biotechnology	16L	402	4.38
Sai Life Sciences Limited	Equity	Pharmaceuticals & Biotechnology	23.6L	359	3.92
Ajanta Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	9.14L	331	3.61
GLAXO SMITHKLINE PHARMA	Equity	Pharmaceuticals & Biotechnology	10.3L	285	3.11
IPCA Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	13.6L	263	2.87
Max Healthcare Institute Limited	Equity	Healthcare Services	26.6L	247	2.70
Vijaya Diagnostic Centre Limited	Equity	Healthcare Services	16.7L	240	2.62
Medplus Health Services Limited	Equity	Retailing	35.5L	232	2.53
Gland Pharma Limited	Equity	Pharmaceuticals & Biotechnology	8.01L	232	2.53
Abbott India Limited	Equity	Pharmaceuticals & Biotechnology	78.5K	213	2.32
Piramal Pharma Limited	Equity	Pharmaceuticals & Biotechnology	99.4L	205	2.24
Thyrocare Technologies Ltd	Equity	Healthcare Services	38.4L	205	2.24
Dr Lal Path Labs Limited	Equity	Healthcare Services	10L	199	2.17
Alkem Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	3.24L	167	1.82
Aurobindo Pharma	Equity	Pharmaceuticals & Biotechnology	9.03L	151	1.65
Narayana Hrudayalaya Limited	Equity	Healthcare Services	8.24L	148	1.61
Suraksha Diagnostic Limited	Equity	Healthcare Services	39L	138	1.51
Syngene International Limited	Equity	Healthcare Services	35L	128	1.40
Emcure Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	6.41L	125	1.36
Pfizer	Equity	Pharmaceuticals & Biotechnology	3.18L	123	1.35
Akums Drugs and Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	13.5L	111	1.21
Anthem Biosciences Limited	Equity	Pharmaceuticals & Biotechnology	12.8L	109	1.19
Fortis Healthcare Limited	Equity	Healthcare Services	13.5L	104	1.13
Biocon	Equity	Pharmaceuticals & Biotechnology	25L	92.7	1.01
Aventis Pharma	Equity	Pharmaceuticals & Biotechnology	3L	91.8	1.00
SANOFI CONSUMER HEALTHCARE	Equity	Pharmaceuticals & Biotechnology	2.14L	81.3	0.89
Molbio Diagnostics Limited	Equity	Healthcare Equipment & Supplies	3.8L	49.8	0.54
Indoco Remedies	Equity	Pharmaceuticals & Biotechnology	16.8L	44	0.48
Astra IDL Ltd	Equity	Pharmaceuticals & Biotechnology	62.6K	38.7	0.42
Concord Biotech Limited	Equity	Pharmaceuticals & Biotechnology	1.12L	15.4	0.17

Fig. 4.Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures.